Introduction
Hendra virus (HeV) and Nipah virus (NiV) are members of the genus Henipavirus, within the family Paramyxoviridae. Nipah virus caused a relatively large outbreak in swine with transmission to humans in Malaysia and Singapore in 1998/1999 [1] , and later human outbreaks in Bangladesh, India and Philippines. The virus was also suspected to be a causative agent of an outbreak in horses in 2014 in the Philippines with transmission to humans [2] . Domestic animals such as cats, dogs, goats and cows were reported to be infected with NiV beside the natural reservoir, mainly pteropus bats [3] . Following the first outbreak in 1994, outbreaks of HeV in horses were reported in Australia, and all cases of human HeV infections were associated with transmission of the virus from horses [4, 5] . Natural infections were reported only in bats and dogs, although experimentally a number of mammalian species can be infected with HeV, including swine [6] [7] [8] .
Due to the high case-fatality rates for henipavirus infections, and lack of human vaccines, both viruses are classified as biosafety level 4 (BSL4) agents. This renders studies on pathogenesis and immune response in vivo difficult, and consequently the current knowledge on virus-host interaction is rather limited. understanding of the host immune response to henipaviruses is essentially based on vaccination studies. The humoral immune response, specifically development of neutralizing antibodies, is considered to be a critical component of the protective immune response in henipavirus infected host [9] [10] [11] [12] . A limited number of reports also suggested the importance of the cellular immune response, at least in swine, horses and hamsters [13] [14] [15] . Vaccine development, production and efficacy testing are similarly complex issues due to the requirement for biosafety and containment level 4 (CL4) for work with henipaviruses.
Despite promising results with the canarypox vectored vaccine candidate [13] , a swine vaccine against NiV is still not available, even though there is a potential for new spill over into swine, considering the outbreak of NiV in horses in 2014 [2] . On the other hand, Equivac HeV Ò vaccine was licensed for use in horses in Australia in 2012. This vaccine, based on a recombinant HeV G protein (sG HEV ), was found to be efficacious against both HeV and NiV in several species, including non-human primates [14, [16] [17] [18] [19] [20] [21] [22] .
Vaccine efficacy testing and understanding protection against henipaviruses may represent a special challenge in swine: Firstly, the porcine host is able to mount an effective immune response in the natural settings [1] . Secondly, the existing experimental model is, despite relatively high challenge dose, not lethal [23] . Thirdly, unlike in other host species, NiV has the ability to infect a range of porcine immune cells, such as dendritic cells, monocytes, macrophages, NK cells and CD8 + T cells [24] , with a highly probable negative impact on the early development of adaptive immune responses. There is indeed indication that the first veterinary vaccine candidate which demonstrated protection against NiV in swine, elicited both, humoral and cellular responses [13] . The aim of this study was to better understand an immune response against henipaviruses in swine, and to identify additional correlates of protection beside the development of neutralizing antibodies.
Material and methods

Cells
Porcine peripheral blood mononuclear cells (PBMC) were isolated using cell collection tubes (CPT; Beckton-Dickinson) according to the manufacturer's instructions. PBMC and Vero 76 cells (ATCC) were cultured as described previously [13, 24] .
Viruses, virus titration and isolation
Second passage of NiV re-isolated from lung of experimentally infected pig and human isolate of HeV, passage No. 6 in Vero 76 cells, were used in the animal infections and for the microtiter plaque reduction neutralization test (mPRNT). Viruses were titrated by plaque assay; virus isolation was performed in a plaque titration format as described previously [8, 13] .
Vaccine candidate
A vaccine candidate based on recombinant soluble HeV G protein (sG HEV ) was provided in ready-to-use format by Zoetis, Inc. in a proprietary adjuvant formulation. Table 1 and Fig. 1) Four-week old Landrace pigs were acclimatized for one week. All animal care and handling protocols were approved by the institutional Animal Care Committee, and met the requirements of the Canadian Animal Care Council (CSCHAH AUD #: C-10-001). The animals were anesthetized with isoflurane in oxygen for all sampling and infection procedures. Components of the studies employing live virus work were conducted under BSL4 conditions at the NCFAD CL4 facility.
Animal experiments (see
Group A: Five pigs were infected orally with 5 Â 10 4 PFU of NiV in 3 ml per pig, and one animal was euthanized at 7 days post infection (dpi) as an infection control. At 28 dpi, a challenge control pig was added to the group, and all animals were challenged intranasally (IN) with 5 Â 10 5 PFU of NiV in 3 ml per pig.
Blood was collected prior to the infection and at 2 dpi; blood and nasal washes were collected at 7, 14, 21 and 28 dpi. Blood and nasal washes were collected at 3 days post challenge (dpc), and all pigs were sampled and euthanized at 5/6 dpc. 2.5. Sample collection (see Table 1 and Fig. 1 ) Nasal washes were collected by lavage of the nasal passages with PBS/0.5% bovine serum albumin (BSA)/1% PenStrep. Blood was collected from the right cranial vena cava directly into serum separator tubes or cell separator tubes. Selected tissues and fluids were collected for virus isolation and viral RNA detection at 5 or 6 dpc: brain (hind cerebrum), trigeminal ganglion, olfactory bulb, cerebrospinal fluid (CSF), spleen, palatine tonsil, nasal turbinates, trachea, lung, cell pellet from the bronchoalveolar lavage (BALF), submandibular and lung associated lymph nodes. Attempts were made to distribute the necropsies representatively: one NiV challenge control pig (group D NiV ) was euthanized at 5 dpc and one at 6 dpc ; two pigs from group A were euthanized at 5 dpc, two at 6 dpc, and two pigs from group C were euthanized at 5 dpc and two at 6 dpc. Two pigs from group B and the HeV challenge control (group D HeV ) were euthanized at 5 dpc and two pigs from group B were euthanized at 6 dpc.
Virus neutralization assay
Serum antibody titers were determined by microtiter plaques reduction neutralization test (mPRNT) as described previously [8, 13] . Wells with reduction of plaques greater than 90% were considered positive for antibody presence.
IgG indirect ELISA
Nunc F flat bottom polystyrene plates were coated with 20 ng/100 ll/well of recombinant NiV G protein sG NIV [16] in 0.06 M carbonate/bicarbonate buffer (pH 9.6) overnight at 4°C. Plates were washed between steps five times with 0.01 M PBS (pH 7.2)/0.05% Tween 20. Plates blocked with 3% BSA/10% horse serum/0.1% Tween 20/0.01 M PBS (pH 7.2) for 1 h at 37°C were incubated for 1 h with 1/100 dilution of pig serum in blocking buffer. Rabbit horseradish peroxidase conjugated anti-porcine antibodies (100 ll/well) (Cedarlane) were added at 1/1000 dilution in blocking buffer for 1 h at 37°C. The incubation was followed by the addition of 100 ll/well of enzyme substrate 2,2 0 -azino-bis[3-ethylbenzothiazoline-6-sulphonic acid] (Roche Diagnostics). OD 405 values were measured using Spectra Max Plus. The indirect sG HEV ELISA was performed as outlined above.
Real time RT-PCR
Viral RNA loads in body fluids and tissue homogenates were determined as described previously for HeV [8] and NiV [24] in samples spiked with 0.5 ll/sample of Armored Enterovirus RNA (Asuragen). Probe 5 0 -TET-CGT GGC GGA ACC GAC TAC TTT GG-NFQ-3 0 within the enterovirus 5 0 -untranslated region, forward CCTGTCGTAACGCGCAAGT and reverse CAGCCACAATAAAA-TAAAAGGAAACA primers were added to the RT-PCR reaction. Reaction products were semi-quantified based on standard curves generated employing plasmid DNA with cloned NiV N or HeV M genes respectively, and the quantities were expressed as log 10 copy numbers/ml. Plates were incubated at 37°C with 5% CO 2 for 5 days. PBMC were harvested by centrifugation at 300 g for 15 min and analyzed by flow cytometry. Interferon gamma (IFN-c) (ABCAM, catalogue #ab113353) and Interleukin 10 (IL-10) (ThermoFisher, catalogue #KSC0101) were assayed in supernatants by ELISA, according to manufacturers' instructions.
Flow cytometry
Non-attached cells from the restimulated PBMCs were re-suspended in 1 ml of MSB (MACS Separation Buffer, Miltenyi Biotec) and labeled in the dark for 30 min at room temperature with a mix of FITC mouse anti-pig CD4a (BD Pharmingen 
Statistics
SigmaPlot 13.0 software was used to generate the graphs, and SAS software (Version 9.4, SAS Institute Inc.) was used for the statistical analysis. Due to low number of animals in the experimental groups non-parametric tests were used for all comparisons.
Comparison of the neutralizing antibody titers (expressed in log 10 ) against NiV versus HeV in the serum samples was analyzed using Student's t-test. The total CD4 + count in PBMC prior and post challenge was also analyzed using Student's t-test. Comparison of ELISA OD values for anti-G antibodies in final (6 dpc) serum samples was analyzed for each group independently using a paired t-test. Kruskal-Wallis test statistic was employed in comparison of groups (viral shedding and CMI analysis). First, to determine whether the groups differed statistically, and in a second step to determine the statistical difference. Statistical significance is reported at P-value equal or less than 0.05.
Results
An overview of the experimental groups is presented in Table 1 and Fig. 1 . Clinical signs (increased rectal temperature) developed only in the challenge control animals, and no adverse reactions were observed following the vaccination with sG HEV . No gross pathological changes which could be ascribed to NiV or HeV infections were observed in pigs during necropsies, including challenge control animals.
Antibody development
NiV infected pigs (group A) started to develop neutralizing antibodies by 14 dpi, and the serum antibodies reached protective levels [13] prior to challenge ( Fig. 2A) . The serum samples where NiV was used as immunizing antigen (group A) showed significantly lower cross-neutralizing activity against HeV (P < 0.001) compared to NiV neutralizing titers.
Pigs vaccinated with sG HEV (groups B and C) required a boost at 21 dpv to develop neutralizing antibodies against HeV however the HeV neutralizing titers reached 320 at 35 dpv. By inference, neutralizing titers equal or above 320 would be considered protective ( Fig. 2B and C) against HeV. The HeV antisera had significantly lower (P < 0.001) cross-neutralizing titers against NiV ( Fig. 2B and C) in comparison to the neutralizing titers against HeV. Consequently, with the highest NiV cross-neutralizing titers prior to the challenge reaching only 80, these antibody levels were not expected to be protective against NiV. All challenge control pigs failed to generate neutralizing antibodies to either HeV or NiV at 5-7 days post challenge (data not shown).
The sera were also tested by an indirect IgG ELISA against sG HEV and against sG NIV for development of antibodies against the G proteins. The levels of anti-G antibodies in NiV infected animals (group A) were notably lower compared to HeV antibodies in vaccinated animals (group B and C) prior to challenge, but did not require a boost for development (Fig. 2D-F) . There appeared to be only partial cross-reactivity of antibodies between HeV and NiV prior to the challenge, clearly noticeable for groups B and C. Due to overall low OD values for group A it was difficult to assess whether there was cross-reactivity with the sG HEV antigen prior to the challenge. However, the OD values of antibodies against the sG HEV and the sG NIV antigen became very close post challenge. The observed cross-reactivity was not considered surprising for group C animals vaccinated with sG HEV and challenged with NiV ( Fig. 2F ) (P = 0.81). Interestingly, there was no statistical difference (P P 0.1) in OD 450 values for anti-G NIV and anti-G HEV antibodies in post-challenge sera at 5/6 dpc of pigs in group A (Fig. 2D ) exposed only to NiV based antigens (P = 0.29) as well as for pigs in group B (Fig. 2E ) exposed only to HeV based antigens (P = 0.24).
In general, the time course of development of anti-G antibodies corresponded with the development of neutralizing antibodies. Fig. 1 . Experimental design. Schematic representation of each group is detailed to indicate sampling, vaccination/inoculation and euthanasia timelines. Group A, primary NiV infection is indicated as days post infection (dpi); while secondary NiV challenge is indicated by days post challenge (dpc). Group B and group C were both vaccinated, therefore dpv represents days post vaccination. Here, dpc represents subsequent challenge with either HeV or NiV as indicated. Group D, challenge control pigs have no pretreatment, therefore no timeline is present prior to challenge. Sampling is indicated by downward facing arrows.
Nasal shedding
Virus RNA shedding in nasal washes was detected in pigs inoculated with NiV (group A) 7 days post primary infection at 4 log 10 copy number/ml, confirming that the animals were indeed infected using lower dose and oral route of infection (Fig. 3) . Post challenge viral RNA shedding was significantly lower for group A compared to NiV challenge control (D NiV ) with P = 0.02 value at 6 dpc, while there was no reduction in RNA shedding in group C (P = 1.0) compared to the challenge control animals (Fig. 3 , NiV challenge panel DAC). Vaccination with sG HEV failed to reduce viral shedding post challenge, compared to respective (D NiV or D HeV ) challenge controls, regardless of the challenge virus (Fig. 3 , HeV challenge panel DB). No infectious virus was isolated from the nasal washes of group A post challenge. The higher amounts of viral RNA detected for nasal washes in the other groups corresponded with successful virus isolation, and the shedding was confirmed in titers of 1.6-2.5 log10 PFU/ml from the post challenge nasal washes. Regretfully, the full set of virus isolation data was not available due to bacterial contaminants in the samples.
Virus detection in tissues
HeV RNA and infectious virus detection are summarized in Fig. 4A . Infectious HeV or viral RNA were not detected in samples from cerebrospinal fluid (CSF), olfactory bulb (OLF), trigeminal ganglion (TGG) or brain of HeV challenged pigs (group B and D HEV ), consistent with a previous report, that HeV may have lower affinity for the CNS in pigs [8] , and the data were omitted from the figure. There was no reduction in viral RNA load in the respiratory tract (nasal turbinates, traches, and lung lavage cell pellet) of vaccinated pigs post challenge. Reduction in viral RNA load was however detected to some extent in the respective draining lymphatic tissues and tonsils (Fig. 4A) . Interestingly, infectious virus was not detected in tissues of any of the sG HEV vaccinated animals post HeV challenge, in contrast to the HeV challenge control, where virus was isolated from cells pelleted from BALF (3.45 log10/PFU per pellet), lung associated lymph nodes (2.4 log 10 PFU/g), tonsils (4.05 log 10 PFU/g) and from submandibular lymph nodes (2.25 log 10 PFU/g) (Fig. 4A, bottom panel) . Thus the data indicated partial protection in the vaccinated animals against HeV challenge.
NiV RNA detection is summarized in Fig. 4B . Nipah virus challenge control animals had RNA (top panel) and infectious virus (bottom panel) present in all tested samples (group D NiV ).
With no infectious virus and almost no viral RNA detected in the tissues after challenge (low levels of RNA detected in tonsils and submandibular lymph nodes), pigs infected with NiV (group A) were considered protected against NiV challenge. Fig. 2A) . Group B are pigs vaccinated with sG HEV and at 35 dpv challenged with HeV (Fig. 2B ). Group C are pigs vaccinated with sG HEV and challenged with NiV (Fig. 2C) . White columns represent the mean (and standard deviation) of antibodies neutralizing NiV, and gray overlapping columns represent the mean (and standard deviation) of antibodies neutralizing HeV. Black arrows indicate boost for vaccinated animals (group B and C). Anti-G antibody development measured by ELISA is plotted in values of optical density at 405 nm in Fig. 2D for group A, Fig. 2E . for group B, and In contrast to group A, NiV RNA was detected post challenge in pigs vaccinated with sG HEV and challenged with NiV (group C), with the exception of the cerebrospinal fluid and the spleen. Infectious virus was detected from BALF cell pellet, OLF and submandibular lymph nodes of three vaccinated pigs (group C) in titers ranging from 1.7 to 4.14 log 10 PFU/g. Lower virus load was detected in lung associated lymph nodes, trachea, nasal turbinates and palatine tonsils (titers ranging from 1.4 to 1.9 log 10 PFU/g) with some animals being negative on virus isolation. Based on this data, the vaccination of pigs with sG HEV did not confer protection against NiV challenge in three out of four animals, although there were noticeable differences in viral RNA load between challenge controls and the group C animals in the following samples: brain, CSF, lung associated lymph nodes and spleen, and no infectious virus was recovered from one pig (No. 19 ).
An interesting preliminary observation was made with the pig euthanized one week post oral infection, and not included in the challenge control group D. This infection route, combined with a somewhat lower dose of virus (2.5 Â 10 4 versus 5 Â 10 5 used in the challenge) resulted in virus detection by RT-PCR only in tonsil, SLN, and nasal swab at 2 dpi (3.85 log 10 copies/ml), and detection of infectious virus in tonsil (2.1 log 10 PFU/g).
Detection of cytokines by indirect ELISA
IFN-gamma and IL-10 production were assessed based on the observation that the two cytokines were upregulated in a previous vaccine efficacy study [13] . PBMC from all animals were restimulated prior to challenge: 28 dpi for NiV infected pigs (Group A) as well as for the sG HEV vaccinated pigs at 35 dpv (group B, C), and also at 5-7 days post challenge. Two doses (50 and 200 ng/ well) of recombinant proteins, sG HEV or sG NIV , were employed in the restimulation assay, but failed to restimulate the PBMC even from the NiV infected pigs (data not shown). In addition, the PBMC restimulation was conducted using either UV inactivated NiV for animals to be challenged with NiV (groups A and C) or UV inactivated HeV for animals in group B (challenged with HeV), both prior to and post challenge. There was no production of IFN-gamma or IL-10 by restimulated PBMC from sG HEV vaccinated pigs or from challenge control pigs, except for the concanavalin A treated control cells. Both cytokines, IFN-gamma and IL-10, were upregulated in cells from pigs in group A (infected orally with NiV and challenged nasally 28 days later) prior to the challenge, and to a lower extent one week post challenge (Fig. 5) .
Since in general, Th1 cells secret IFN-gamma, and Th2 cells secrete IL-10, these data indicated that both Th1 and Th2 responses were activated in the restimulated cells from infected animals prior to challenge. However NiV infection appeared to downregulate IFN-gamma as well as IL-10 during the acute phase of the challenge (Fig. 5) .
T-cell response
Activation of the T-cell response was assessed by labeling three cell markers: CD4, CD8, and the activation marker CD25. Current literature on swine immune cells, identifies the following T-cell populations based on these markers: CD4 and upregulate CD25 as well [33] . As anticipated, no CD25 upregulation was observed for the CD4 + CD8
À population (Fig. 6A) .
Upregulation of the CD25 marker was detected only in PBMCs from pigs in the group A on CD4 + CD8 + (predominantly T helper memory) cells and on CD4 À CD8 + (predominantly cytotoxic T) cells (Fig. 6A) . The CD4 À CD8 + cells (with both memory and effector T cells in this population, and likely containing also NK cells) were analyzed as one population when comparing all the experimental groups, as we were unable to distinguish cell populations based on intensity of staining for the CD8 marker in groups B and C. There was a statistically significant difference in the restimulation of CD4 Approximately 25% of cells in the gate N were CD4 À CD8 + indicating restimulation of the cytotoxic T memory cells.
To assess the effect of the recombinant proteins on restimulation, three doses of either sG HEV or sG NIV, were administered (50, 100 and 200 ng/well). Interestingly, both sG HEV and sG NIV failed to elicit any observable effect in PBMCs. Further, even in PBMCs generating a positive response to UV inactivated virus (group A), the recombinant sG HEV or sG NIV would not elicit a response (data not shown).
Difference in total CD4 + cell population in naïve (group D) and protected (group A) animals following NiV infection was observed in the unstimulated PBMC controls before and after challenge. The analysis indicated a drop in the total CD4 + population post challenge in NiV challenge control pigs (group D) (P < 0.001), whereas there was no statistical difference in CD4 + population frequency pre and post challenge in unstimulated PBMC from pigs in group A (Fig. 6D ).
Discussion
The aim of this study was to elucidate factors involved in protective immune response in pigs against henipaviruses using experimental infection or immunization with sG HEV .
Based on the requirement for henipavirus veterinary vaccines to interrupt transmission among pigs and importantly to humans, and based on previous experimental work [13] , the following parameters were evaluated: infectious virus and viral RNA load in tissues and nasal washes (an indicator of shedding), development of antibodies, and development of adaptive cellular immune response. Disease prevention was not considered a reliable parameter of protection since in agreement with previous studies [34] clinical signs were observed post infection/challenge in only two of eight pigs (transient increase in rectal temperature).
Protection against nasal henipavirus challenge was evaluated in pigs vaccinated with adjuvanted sG HEV or orally infected with NiV (group A). Vaccinated pigs were challenged either with HeV (group B) or NiV (group C).
Animals in group A were considered protected against NiV challenge based on the significant reduction of viral RNA shedding and viral RNA load in tissues and body fluids at post mortem examination, and lack of detection of infectious virus.
As for groups B and C, based on the analysis of neutralizing antibodies, protective titers (160-320) were reached against HeV in sG HEV vaccinated animals, but not against NiV (titers of 40-80). As expected, sG HEV vaccinated animals challenged with NiV (group C) were not protected against NiV challenge. Surprisingly, the HeV vaccinated animals (Group B), expected to be protected against HeV challenge based on the neutralizing antibodies levels were only partially protected. Although there was some reduction in virus RNA load in tissues and no infectious virus was isolated from the tissues, there was no reduction of viral RNA in nasal washes and the pigs were shedding infectious virus early post infection.
Analysis of neutralizing activity of the sera revealed a low crossneutralization of NiV by G HEV antibodies. In contrast, Mungall and colleagues [16] reported high cross-neutralization in serum from cats vaccinated with G HEV against NiV, while serum from cats vaccinated with G NIV had lower cross-neutralizing activity against HeV. Several animal models vaccinated with G HEV were crossprotected against NiV [16, 18, 21, 22] . Interestingly, attempts to cross-protect hamsters against HeV by vaccination with G NIV were only partially successful compared to protection against NiV [35] . Differences in cross-reactivity of anti-G antibodies determined by ELISA prior to the challenge were also apparent. Whether the observed lack of cross-reactivity between the anti-G antibodies generated against NiV or HeV is unique to swine, is difficult to assess at this time. Interestingly, anti-G antibody levels detected by ELISA in vaccinated animals were significantly higher than in the infected animals (group A) while exhibiting similar neutralizing activity against their respective viruses: a higher concentration of HeV anti-G antibodies were required to obtain the same neutralizing titers against HeV compared to the anti-G antibody levels in serum of NiV infected piglets required for NiV neutralization (Fig. 2) . This underlines the role of additional viral proteins in eliciting neutralizing antibodies, such as the fusion F protein [13] .
Analysis of the CMI response prior to challenge revealed that there were no detectable immune memory cells generated in response to immunization with G HEV , while pigs infected with NiV (group A) developed antigen-specific immune memory cells (Th and Tc). Interestingly, the CD4 + cell population remained stable following the challenge compared to the control pigs. This is a potential indicator of protection that has been suggested previously [24] and requires further studies. Upregulation of IFN-gamma (typically secreted by Th1 cells) and IL-10 (typically secreted by Th2 cells) prior to challenge suggested that the oral infection with NiV lead to development of cellular memory with both Th1 and Th2 responses activated. The observed down-regulation of IL-10 and IFN-gamma in PBMC restimulated post-challenge is in agreement with the proposed immune-modulating characteristics of NiV during the acute phase of the infection [36] [37] [38] . Expression of IFN-gamma and IL-10 was downregulated along with IL-6, IL-4 and IL-1beta in the brain of NiV infected hamsters early post infection [37] . However, since in cell culture, NiV infected human dendritic cells were able to up-regulate IL-10 [39] , the IL-10 block in vivo may be connected to IL-12 production. Despite the fact that NiV infects multiple types of porcine immune cells leading to the proposed downregulation of Th1 and Th2 responses, and the fact that NiV non-structural proteins interfere with a number of regulatory pathways in the infected immune cells [40, 41] resulting in skewed cytokine responses, the orally infected pigs developed humoral and cellular immune memory, and were able to mount an efficient protective immune response against NiV challenge. Studies elucidating the complex NiV virus -host interactions in swine may facilitate better understanding and development of treatment and vaccination strategies in humans and other species, albeit indirectly.
In addition, the present study confirmed the susceptibility of pigs to HeV even using much lower dose of 2.5 Â 10 5 PFU/animal.
The observed difference between HeV and NiV invasion of CNS in this study indicates that there may be a difference between the two viruses in their propensity to invade CNS. This would be in agreement with the previous pilot study employing a higher dose of HeV 10 7 PFU/animal [8] .
As a number of publications demonstrated efficacy of the sG HEV vaccine candidates against both HeV and NiV in several species [14, [16] [17] [18] [20] [21] [22] , consideration was given to the sG HEV as a potential vaccine candidate in pigs as well. By demonstrating partial protection in sG HEV vaccinated animals challenged with HeV, the current study indicates, that vaccine formulation inducing cellular immunity may be efficacious in pigs, and warrants further work on developing sG HEV or more likely sG NIV as a vaccine against NiV in swine.
In conclusion, this work demonstrated that both arms of the immune response are critical for the protection of swine against henipaviruses. The study clearly underlined the importance of an adaptive cell-mediated immune response in protection against Hendra and Nipah virus. The sG HEV combined with an adjuvant stimulating cellular immune response should be again evaluated as a vaccine candidate against NiV in swine.
